These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10779888)

  • 1. Estrogen receptor activation and tardive dyskinesia.
    Turrone P; Seeman MV; Silvestri S
    Can J Psychiatry; 2000 Apr; 45(3):288-90. PubMed ID: 10779888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
    Bressan RA; Jones HM; Pilowsky LS
    J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D3 receptor variant and tardive dyskinesia.
    Rietschel M; Krauss H; Müller DJ; Schulze TG; Knapp M; Marwinski K; Maroldt AO; Paus S; Grünhage F; Propping P; Maier W; Held T; Nöthen MM
    Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):31-5. PubMed ID: 10738862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R
    Can J Psychiatry; 2005 Aug; 50(9):541-7. PubMed ID: 16262110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic-induced tardive dyskinesia.
    Jenner P; Marsden CD
    Acta Psychiatr Belg; 1987; 87(5):566-98. PubMed ID: 2897761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia due to aripiprazole: report of 2 cases.
    Lungu C; Aia PG; Shih LC; Esper CD; Factor SA; Tarsy D
    J Clin Psychopharmacol; 2009 Apr; 29(2):185-6. PubMed ID: 19512985
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.
    Trugman JM; Leadbetter R; Zalis ME; Burgdorf RO; Wooten GF
    Mov Disord; 1994 Jul; 9(4):441-6. PubMed ID: 7969212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schizophrenia, tardive dyskinesia, and a D3 receptor gene variant: a new twist on dyskinesias?
    Jeste DV; Kelsoe JR
    Mol Psychiatry; 1997 Mar; 2(2):86-8. PubMed ID: 9106222
    [No Abstract]   [Full Text] [Related]  

  • 12. Sulpiride in tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand Suppl; 1984; 311():93-102. PubMed ID: 6142590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.
    Duggal HS; Mendhekar DN
    Am J Psychiatry; 2006 Aug; 163(8):1449-50. PubMed ID: 16877664
    [No Abstract]   [Full Text] [Related]  

  • 14. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
    Cho CH; Lee HJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics.
    Woo SI; Kim JW; Rha E; Han SH; Hahn KH; Park CS; Sohn JW
    Psychiatry Clin Neurosci; 2002 Aug; 56(4):469-74. PubMed ID: 12109967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia.
    Ivanova SA; Al Hadithy AF; Brazovskaya N; Semke A; Wilffert B; Fedorenko O; Brouwers JR; Loonen AJ
    Hum Psychopharmacol; 2012 May; 27(3):334-7. PubMed ID: 22585593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive dyskinesia.
    Soares-Weiser K; Fernandez HH
    Semin Neurol; 2007 Apr; 27(2):159-69. PubMed ID: 17390261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.